Security key
71902K303
CERO THERAPEUTICS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (CERO)
CUSIP: 71902K303
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 5,523
- Total 13F value
- $331
- Share change
- 0
- SEC-reported price per share
- $0.06
- Number of holders
- 1
- Shares outstanding
- 5,851,331
Holder snapshot
3 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
1
Top holders
1
CERO full security history
Ownership snapshot
Full 13F holder table
CERO THERAPEUTICS HOLDINGS, INC. SEC filings
CERO THERAPEUTICS HOLDINGS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of CERO - CERO THERAPEUTICS HOLDINGS, INC. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Stuart M. Sloan
Disclosed value leader
Stuart M. Sloan
Comparable rows
0/15
Latest evidence
11 Dec 2024
3/4/5
13D/G
13F
Highest disclosed value: $2,197,388
15 rows are not safely comparable across share classes.
13D/G row: YK Bioventures Opportunities GP I, LLC
Showing 1-6 of 15 holder rows.
Quick read
Stuart M. Sloan has the largest disclosed position value at $2.2M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens YK Bioventures Opportunities GP I, LLC's linked filing trail.
Disclosed position value
Top 5
Stuart M. Sloan
$2.2M
YK Bioventures Opportunities GP I...
$780.3K
PHOENIX BIOTECH SPONSOR, LLC
$100K
Douglas Carl Fisher
$483K
ARCH Venture Management, LLC
$134.8K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Stuart M. Sloan |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$2,197,388
21,067,956 shares
|
— | 25 Sep 2024 |
| YK Bioventures Opportunities GP I, LLC |
3/4/5
13D/G
10%+ Owner
|
—
denominator unverified
|
$780,310
13,005,169 shares
|
— | 11 Dec 2024 |
| PHOENIX BIOTECH SPONSOR, LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$100,000
1,000,000 shares
|
— | 14 Feb 2024 |
| Douglas Carl Fisher |
3/4/5
President
|
—
mixed-class rows
|
$483,000
48,350 shares
mixed-class rows
|
— | 14 Feb 2024 |
| ARCH Venture Management, LLC |
13F
Company
|
—
denominator unverified
|
$134,753
1,444,296 shares
|
— | 30 Sep 2024 |
| Avantax Planning Partners, Inc. |
13F
Company
|
—
denominator unverified
|
$126,993
1,361,130 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
5,523
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
0
Q4 2024 holders
1
Holder diff
1
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|